Article

Santen CEO appointed to OccuLogix Board

OccuLogix Inc. has appointed Adrienne L. Graves, PhD, president and CEO of Santen Inc., to its board of directors.

May 3

- Fort Lauderdale, FL - OccuLogix Inc. has appointed Adrienne L. Graves, PhD, president and CEO of Santen Inc., to its board of directors.

The healthcare company, which is involved in bringing innovative and evidence-based medical therapies to market, chose Dr. Graves because of her experience with clinical, regulatory, and commercial development of products within the ophthalmic industry. Under her leadership, Santen's research and development team successfully developed and obtain FDA approval for three ophthalmic products in major therapeutic areas.

"On behalf of the staff and board of OccuLogix, I would like to welcome Dr. Graves," said Elias Vamvakas, OccuLogix's chairman and CEO. "We all look forward to working with Adrienne and benefiting from her valuable involvement in the development of the RHEO procedure."

Dr. Graves is the author of more than 30 research papers. She is a member of a number of professional associations, including the Association for Research in Vision and Ophthalmology, the American Academy of Ophthalmology, the American Glaucoma Society, and Women in Ophthalmology. In addition, Dr. Graves co-founded Ophthalmic Women Leaders with Marguerite McDonald, MD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.